Breaking tolerance with engineered class I antigen-presenting molecules.

Area of Science:

• Immunology
• Cancer Research
• Vaccinology

Background:

• Activating T cells against weak cancer antigens often uses altered peptide antigens, requiring detailed knowledge of specific ligands.
• Allorecognition, the immune response to non-self antigens, offers an alternative strategy for T cell activation.

Purpose of the Study:

• To explore allorecognition as a method for activating cytotoxic T lymphocytes (CTLs) against weak or self-antigens presented by self-MHC.
• To develop a T cell activation strategy that circumvents the need for detailed knowledge of altered peptide ligands.

Main Methods:

• Engineered variants of MHC class I molecules with substitutions in conserved helical domains were designed.
• These variants were used to activate alloreactive CD8 T cells without altering naturally bound peptide ligands.
• The ability of activated CTLs to break self-tolerance and react to self-peptide-MHC complexes was assessed.

Main Results:

• MHC class I variants successfully activated alloreactive CD8 T cells, providing strong signaling.
• These activated CTLs demonstrated the ability to recognize and react against self-peptides presented by native MHC.
• The engineered approach enabled T cells to overcome self-tolerance.

Conclusions:

• Allorecognition via engineered MHC class I variants is a viable strategy for activating T cells against tumor-associated antigens.
• This method offers a potential new avenue for cancer vaccines by inducing autoimmunity against tumors.
• The approach allows for the activation of self-tolerant T cells to target cancer cells effectively.